NUFORMIX PLC

AGM Information • Mar 19, 2024

National Storage Mechanism | Additional information

RNS Number : 4695H

Nuformix PLC

19 March 2024

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting ("AGM") of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved by way of a poll vote.  The results of the poll, including proxies received ahead of the AGM, are reported below:

	Resolution	Ordinary/ Special	For		Against		Total votes cast
			No. of votes	%	No. of votes	%
1	To receive the annual report and accounts for the year ended 30 September 2023	Ordinary	142,381,407	97.38%	3,824,784	2.62%	146,206,191
2	To approve the annual report on remuneration	Ordinary	142,812,526	97.60%	3,505,839	2.40%	146,318,365
3	To re-appoint Daniel Gooding as a director	Ordinary	141,901,631	97.81%	3,179,490	2.19%	145,081,121
4	To re-appoint Julian Gilbert as a director	Ordinary	141,901,631	97.81%	3,179,490	2.19%	145,081,121
5	To re-appoint Madeleine Kennedy as a director	Ordinary	141,881,631	97.75%	3,270,050	2.25%	145,151,681
6	To re-appoint Kreston Reeves LLP as auditor	Ordinary	142,139,182	97.90%	3,055,316	2.10%	145,194,498
7	To authorise the directors to determinethe auditor's fees	Ordinary	141,874,740	97.71%	3,319,758	2.29%	145,194,498
8	To authorise the directors to allot shares	Ordinary	136,385,306	93.95%	8,785,230	6.05%	145,170,536
9	To authorise the directors to disapply pre-emption rights	Special	134,565,189	92.73%	10,553,347	7.27%	145,118,536
10	To authorise the Company to purchase its own shares	Special	135,812,749	94.11%	8,504,877	5.89%	144,317,626
11	To authorise calling of a general meeting on 14 clear days' notice	Special	142,106,241	97.84%	3,141,610	2.16%	145,247,851

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 819,309,368 ordinary shares of £0.001 each.

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	+44 (0) 20 3650 3650
Bob Pountney (Corporate Broking)	+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit  www.nuformix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGZKLFFZXLXBBV